Catheter Caps for Dialysis

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Mayo Clinic
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new device called the Catheter Caps Case (C3) to assess its comfort and ease of use for dialysis patients. It targets individuals with a hemodialysis catheter undergoing regular dialysis. Those with a tunneled dialysis catheter that will not be removed soon and without acute kidney issues might be suitable candidates. As an unphased trial, this study provides a unique opportunity to contribute to the development of innovative solutions for dialysis care.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this device is safe for dialysis patients?

Research shows that the Catheter Caps Case (C3) aims to make dialysis more comfortable for patients. Although detailed safety information from past studies is lacking, this trial is marked as "Not Applicable" in phase, indicating that the main goal isn't to test safety as in early drug trials. This suggests the device is likely low-risk.

Since the focus is on a device, not a drug, safety concerns may differ. If C3 resembles other caps used in dialysis, such as those designed to fight germs, they are usually well-tolerated by patients. These caps help prevent infections at the catheter insertion site, a common issue in dialysis. Overall, despite the absence of specific safety data for C3, the trial's nature and the performance of similar devices suggest it should be safe to use.12345

Why are researchers excited about this trial?

Researchers are excited about the Catheter Caps Case (C3) because it offers a potentially safer and more effective way to prevent infections for patients undergoing dialysis. Unlike traditional catheter caps, which can sometimes fall short in preventing bacterial contamination, C3 is designed with an innovative sealing mechanism that enhances its antimicrobial protection. This new approach could significantly reduce the risk of infections, which is a major concern for patients with dialysis catheters. By improving safety and potentially reducing complications, C3 could lead to better patient outcomes and a higher quality of life for those relying on dialysis.

What evidence suggests that the Catheter Caps Case (C3) is effective for dialysis patients?

Research has shown that catheter caps coated with chlorhexidine greatly reduce infections in dialysis patients. Studies have found that these caps lower the risk of bloodstream infections, which are common in patients with central venous catheters. Chlorhexidine, an antiseptic, helps keep the catheter area clean and reduces germs. Patients report that these caps are more comfortable and easier to use than traditional methods. These findings suggest that the Catheter Caps Case (C3) could make dialysis safer and more comfortable.12678

Are You a Good Fit for This Trial?

This trial is for dialysis patients who use a hemodialysis catheter. It's designed to assess how comfortable and easy it is to use a new device called Catheter Caps Case (C3) over a short period.

Inclusion Criteria

Patients with tunneled dialysis catheter that will not be removed in the next 90 days
I am a patient receiving dialysis, either at home or in a center.

Exclusion Criteria

Allergies to the BioMed Elastic 50A Resin
Patients with non-tunneled catheter
I am currently experiencing acute kidney injury.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants use the Catheter Caps Case (C3) attached to the hemodialysis catheter for evaluation over a 15-minute period

1 day
1 visit (in-person)

Follow-up

Participants are monitored for any immediate reactions or issues following the use of the Catheter Caps Case

1 day

What Are the Treatments Tested in This Trial?

Interventions

  • Catheter Caps Case (C3)
Trial Overview The study is testing the Catheter Caps Case (C3), which attaches to the hemodialysis catheter. The focus is on patient comfort and ease of use during a brief, 15-minute evaluation period.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

Citations

Dialysis Catheter Caps Case Feasibility StudyThe purpose of this research is to evaluate patient comfort and ease of an investigational device called Catheter Caps Case (C3) attached to ...
Catheter Caps for Dialysis · Info for ParticipantsThe purpose of this research is to evaluate patient comfort and ease of an investigational device called Catheter Caps Case (C3) attached to the ...
Evaluating a Novel Hemodialysis Central Venous Catheter ...An initial assessment found that a substantial CLABSI rate reduction was seen with use of chlorhexidine-coated end caps; therefore, most ...
4.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/41027634/
Using Chlorhexidine-Coated Dialysis Catheter Caps to ...Conclusions: Use of chlorhexidine-coated dialysis catheter caps led to clinically significant results among patients receiving dialysis with ...
Central Venous Catheters in Dialysis: The Good, the Bad ...In this article we present the pros and cons of CVC, in addition to the different complications and excessive economical costs related to their use.
ClearGuard™ HD Antimicrobial Barrier CapsClinically proven to reduce the rate of CLABSIs in hemodialysis catheter patients · Catheter infections are frequent, costly, and deadly · Reduce hemodialysis ...
NHSN Patient Safety Component ManualPlease Note: The NHSN Patient Safety Component Manual is updated annually based on subject matter expert review and user feedback.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security